Cytek Biosciences, Inc. (CTKB): A Bull Case Theory

This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return potential, read our free article: 10 Promising SmallCap Stocks Under $1 Billion Market Cap.

We came across a bullish thesis on Cytek Biosciences, Inc. on Valueinvestorsclub.com by diamond123. In this article, we will summarize the bulls’ thesis on CTKB. Cytek Biosciences, Inc.’s share was trading at $3.2400 as of July 16^th.

Cytek Biosciences (CTKB) presents a uniquely attractive setup, combining leading-edge technology in flow cytometry with strong financials, meaningful downside protection, and misunderstood market pessimism. The company’s flagship Full Spectrum Profiling (FSP) platform, launched with the Aurora in 2017, has enabled labs to significantly expand marker analysis per sample at lower cost, smaller footprint, and better usability versus legacy systems.

Its patented laser system and unmixing software underpin a suite of differentiated products, including the Aurora CS and upcoming launches in clinical-use and integrated imaging models, both expanding the total addressable market. Despite cyclically weak medical research funding, Cytek remains EBITDA-profitable, generates positive free cash flow, and benefits from a growing recurring revenue stream—now 30% of sales—from reagents, software, and services.

Gross margins remain high (~58%), supported by proprietary manufacturing. Importantly, Cytek trades at an implied enterprise value under $50 million, with $265 million in net cash and ~$0.37/share in working capital, suggesting investors are paying a fraction of revenue for a profitable, IP-rich business. The company is repurchasing stock, and management—who owns over 10%—has signaled disciplined capital allocation, including M&A. While competition from incumbents like BD and Sony remains, Cytek continues to take share due to usability and pricing. End-user feedback confirms high satisfaction, and broader adoption appears to be underway.

Catalysts include improving industry sentiment, expansion of recurring revenue, product launches, and potential buybacks or acquisitions. With its rare blend of strong fundamentals, dominant IP, and strategic optionality, Cytek is well-positioned for multiple reratings as sentiment rebounds, with limited downside at current valuation.

Previously, we covered a bullish thesis on Rapid Micro Biosystems, Inc. (RPID) by Borlaug in April 2025, which highlighted the company’s automation-led disruption in microbial quality control, its razor-and-blade model, and validation through key partnerships. The company’s stock price has appreciated by approximately 28.62% since our coverage. This is because recurring revenues and margins improved sharply. Diamond123 shares a similar view on Cytek Biosciences (CTKB) but emphasizes its leadership in flow cytometry and balance sheet strength.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None.